Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disease-modifying Therapies for Multiple Sclerosis.

John R. Corboy1, Douglas S. Goodin, Elliot M. Frohman

  • 1Department of Neurology, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, B183, Denver, CO 80262, USA. john.corboy@UCHSC.edu

Current Treatment Options in Neurology
|January 11, 2003
PubMed
Summary

Multiple sclerosis (MS) treatments like interferon-beta and glatiramer acetate are most effective early. While treatments exist for relapsing-remitting and secondary progressive MS, primary progressive MS currently lacks effective therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bladder, Bowel, and Sexual Dysfunction in Multiple Sclerosis.

Current treatment options in neurologyยท2001
See all related articles

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a suspected autoimmune disorder with incomplete immunotherapeutic treatments.
  • Current therapies are most effective early in the disease course, particularly for relapsing forms.

Purpose of the Study:

  • To review the efficacy of current immunotherapies for different forms of multiple sclerosis.
  • To provide guidance on treatment choices based on disease subtype and patient needs.

Main Methods:

  • Review of Class I data from large clinical trials on MS treatments.
  • Analysis of comparative data and outcomes for interferon-beta (IFNbeta) and glatiramer acetate.
  • Evaluation of treatment effectiveness in relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS).

Related Experiment Videos

Main Results:

  • Interferon-beta-1a, interferon-beta-1b, and glatiramer acetate are supported by Class I data for RRMS.
  • Higher doses or more frequent administration of IFNbeta may improve outcomes but increase side effects and antibody production.
  • IFNbeta shows efficacy in reducing MRI lesion progression in SPMS, though clinical outcomes are less clear.
  • No effective therapies are currently established for PPMS.

Conclusions:

  • All RRMS patients, except those with benign MS, should consider treatment with interferons or glatiramer acetate.
  • Early initiation of therapy, especially after a clinically isolated syndrome (CIS) with high RRMS risk, is recommended.
  • IFNbeta is justifiable for SPMS, and mitoxantrone may be considered for slowing progression, with careful risk assessment.
  • There is currently no medical justification for treating PPMS with available agents.